FTM
First Turn Management Portfolio holdings
AUM
$536M
This Quarter Return
+14.87%
1 Year Return
+36.36%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$536M
AUM Growth
+$536M
(+8.1%)
Cap. Flow
-$21.4M
Cap. Flow
% of AUM
-3.98%
Top 10 Holdings %
Top 10 Hldgs %
46.73%
Holding
42
New
7
Increased
14
Reduced
14
Closed
7
Top Buys
| 1 |
Disc Medicine
IRON
|
$15.9M |
| 2 |
Arcellx
ACLX
|
$14.2M |
| 3 |
ADMA Biologics
ADMA
|
$9.57M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$9.44M |
| 5 |
Akero Therapeutics
AKRO
|
$6.11M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$13.4M |
| 2 |
Glaukos
GKOS
|
$13.4M |
| 3 |
Exact Sciences
EXAS
|
$13M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$11.9M |
| 5 |
Vaxcyte
PCVX
|
$10.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $37.5M | 7% | 372,672 -28,957 | -7% | -$2.91M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $29.3M | 5.47% | 309,988 -125,397 | -29% | -$11.9M |
|
3
Mirum Pharmaceuticals
MIRM
$3.71B
| $26.8M | 5.01% | 527,540 +24,526 | +5% | +$1.25M |
|
4
Nuvalent
NUVL
$5.52B
| $24.5M | 4.57% | 320,798 -11,129 | -3% | -$849K |
|
5
argenx
ARGX
$43.6B
| $24.2M | 4.52% | 43,953 +2,042 | +5% | +$1.13M |
|
6
BridgeBio Pharma
BBIO
$9.89B
| $23.8M | 4.44% | 551,684 -105,015 | -16% | -$4.53M |
|
7
Ascendis Pharma
ASND
$11.8B
| $23.2M | 4.34% | 134,687 +21,409 | +19% | +$3.7M |
|
8
Xenon Pharmaceuticals
XENE
$2.98B
| $20.7M | 3.86% | 660,617 -22,834 | -3% | -$715K |
|
9
Oric Pharmaceuticals
ORIC
$994M
| $20.4M | 3.81% | 2,009,923 -17,507 | -0.9% | -$178K |
|
10
Natera
NTRA
$23.1B
| $20M | 3.72% | 118,130 -21,812 | -16% | -$3.68M |
|
|
11
ADMA Biologics
ADMA
$4.12B
| $19.9M | 3.71% | 1,092,361 +525,416 | +93% | +$9.57M |
|
12
Intuitive Surgical
ISRG
$170B
| $17.6M | 3.28% | 32,305 +10,196 | +46% | +$5.54M |
|
13
Insulet
PODD
$23.9B
| $16.2M | 3.01% | 51,408 +2,058 | +4% | +$647K |
|
14
TG Therapeutics
TGTX
$4.65B
| $16.1M | 3.01% | 447,884 +47,240 | +12% | +$1.7M |
|
|
15
Disc Medicine
IRON
$2.07B
| $15.9M | 2.96% | +299,464 | New | +$15.9M |
|
16
Guardant Health
GH
$8.41B
| $15.7M | 2.93% | 302,307 -13,430 | -4% | -$699K |
|
17
Merus
MRUS
$4.98B
| $15.4M | 2.87% | 292,964 -170,996 | -37% | -$8.99M |
|
18
Revolution Medicines
RVMD
$7.1B
| $15.3M | 2.85% | 415,591 +75,482 | +22% | +$2.78M |
|
19
Axsome Therapeutics
AXSM
$6.05B
| $15.1M | 2.81% | 144,400 +26,221 | +22% | +$2.74M |
|
20
Boston Scientific
BSX
$156B
| $14.9M | 2.78% | 138,834 -39,322 | -22% | -$4.22M |
|
|
21
Arcellx
ACLX
$3.85B
| $14.2M | 2.64% | +215,223 | New | +$14.2M |
|
22
Apogee Therapeutics
APGE
$2.17B
| $13.5M | 2.52% | 311,490 +81,815 | +36% | +$3.55M |
|
23
RadNet
RDNT
$5.52B
| $11.3M | 2.1% | 197,759 +40,144 | +25% | +$2.28M |
|
24
Janux Therapeutics
JANX
$1.37B
| $10.3M | 1.93% | 447,420 +17,257 | +4% | +$399K |
|
25
Enliven Therapeutics
ELVN
$1.2B
| $10.2M | 1.91% | 509,987 -25,105 | -5% | -$504K |
|